Actos

Important Update: Results from a Canadian study suggest that patients who take the diabetes medication Actos for more than two years have a doubled risk of developing bladder cancer. Researchers who conducted the study analyzed records of more than 115,000 Actos patients. The study was published by the British Medical Journal on May 29, 2012.

The U.S. Food and Drug Administration (FDA) said in a June 15, 2011 warning that it is reviewing data from an ongoing study that seeks to determine if Actos (pioglitazone) causes bladder cancer. The FDA said other studies have found a connection between Actos and bladder cancer and that it plans to update the public once more information is available.

According to the FDA warning, the agency has found a possible increase in the risk of bladder cancer in patients that are treated with the diabetes drug for long periods of time and at high doses. The agency said it did not find a risk for all Actos patients.

France and Germany Pull Actos from Market Due to Bladder Cancer Risk

The warning follows an announcement that pioglitazone was pulled from the shelves in France and Germany due to the risk of bladder cancer.

Bladder cancer can spread to nearby organs if it is not treated in time. Patients taking Actos should see their doctors if they experience any unusual signs or symptoms. The most common bladder cancer symptom is blood in the urine. Other symptoms include pain when urinating, frequent urination, urinary tract infections (UTI) and pain in the lower back.

If you or someone you love has taken Actos and have been diagnosed with bladder cancer contact the lawyers of Aylstock, Witkin, Kreis & Overholtz at (844) 794-7402 for a case evaluation.

More Actos News From Our Blog